239,749 Shares in Vaxcyte, Inc. $PCVX Bought by University of Wisconsin Foundation

Posted by Geri Gentry on Aug 25th, 2026

University of Wisconsin Foundation bought a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 239,749 shares of the company’s stock, valued at approximately $13,937,000. Vaxcyte makes up approximately 11.0% of University of Wisconsin Foundation’s portfolio, making the stock its 4th largest position.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Legal & General Group Plc purchased a new stake in Vaxcyte in the 2nd quarter worth $5,665,000. The Manufacturers Life Insurance Company bought a new position in shares of Vaxcyte during the 2nd quarter valued at about $6,307,000. Spruce Street Capital LP purchased a new position in shares of Vaxcyte during the second quarter valued at about $17,790,512,000. Algert Global LLC grew its position in shares of Vaxcyte by 41.6% during the second quarter. Algert Global LLC now owns 515,343 shares of the company’s stock valued at $29,957,000 after purchasing an additional 151,359 shares in the last quarter. Finally, Sanctuary Advisors LLC bought a new stake in shares of Vaxcyte in the second quarter worth about $325,000. 96.78% of the stock is currently owned by institutional investors.

Vaxcyte Stock Down 1.2%

PCVX stock opened at $61.87 on Tuesday. Vaxcyte, Inc. has a 52 week low of $29.87 and a 52 week high of $65.00. The company has a fifty day simple moving average of $56.67 and a two-hundred day simple moving average of $55.84. The firm has a market capitalization of $9.21 billion, a P/E ratio of -8.11 and a beta of 1.23.

Vaxcyte (NASDAQ:PCVX – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.06) by $0.09. During the same quarter in the prior year, the company earned ($1.22) earnings per share. As a group, analysts anticipate that Vaxcyte, Inc. will post -7.6 EPS for the current year.

Insider Buying and Selling

In other news, insider Harpreet S. Dhaliwal sold 17,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $55.00, for a total value of $935,000.00. Following the completion of the sale, the insider directly owned 76,756 shares of the company’s stock, valued at $4,221,580. This trade represents a 18.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $53.86, for a total value of $121,185.00. Following the transaction, the chief operating officer directly owned 157,541 shares in the company, valued at approximately $8,485,158.26. This represents a 1.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 120,646 shares of company stock valued at $6,570,810. 3.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on PCVX. Zacks Research upgraded Vaxcyte from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Wall Street Zen upgraded Vaxcyte from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research note on Monday, July 6th. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $86.00.

Check Out Our Latest Stock Report on Vaxcyte

About Vaxcyte

(Free Report)

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.